Clinical studies focusing on melanoma, RCC, squamous cell carcinoma, and NSCLC have shown remarkable increases in patient survival with both CTLA-4 and PD-1 checkpoint inhibitors compared to conventional chemotherapy (89). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.